Newcastle disease virus (strain Herts 33/56) in tissues and organs of chickens infected experimentally

被引:19
作者
Alexander, DJ [1 ]
Manvell, RJ [1 ]
Parsons, G [1 ]
机构
[1] Vet Labs Agcy Weybridge, Dept Virol, Addlestone KT15 3NB, Surrey, England
关键词
D O I
10.1080/03079450600597444
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Six-week-old susceptible specific pathogen free chickens were infected intranasally with the virulent Newcastle disease virus strain Herts 33/56 and the levels of virus present in blood, faeces, breast muscle, leg muscle and a pool of heart/kidney/spleen were estimated in birds killed humanely at each day post inoculation. Highest titres were recorded at day 4 post inoculation when titres of virus were 10(6) median egg infectious doses ( EID50)/g in the heart/kidney/spleen pool, 10(4.2) EID50/g in the leg muscle and 10(4) EID50/g in the breast muscle and faeces. A median oral infectious dose of Newcastle disease virus strain Herts 33/56 for 3-week-old chickens was estimated to be equivalent to 10(4) EID50.
引用
收藏
页码:99 / U7
页数:4
相关论文
共 9 条
[1]  
Allan W H, 1978, FAO ANIMAL PRODUCTIO, V10
[2]   Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus [J].
Capua, I ;
Terregino, C ;
Cattoli, G ;
Toffan, A .
AVIAN PATHOLOGY, 2004, 33 (02) :158-163
[3]   Risks of transmitting Newcastle disease by infected poultry products [J].
Guittet, M ;
LeCoq, H ;
Picault, JP .
REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES, 1997, 16 (01) :79-82
[4]   A comparison of the onset of protection induced by Newcastle disease virus strain B1 and, a fowl poxvirus recombinant Newcastle disease vaccine to a viscerotropic velogenic Newcastle disease virus challenge [J].
King, DJ .
AVIAN DISEASES, 1999, 43 (04) :745-755
[5]  
Lamb R.A., 2000, VIRUS TAXONOMY CLASS, P549
[6]  
LANCASTER JE, 1966, MONOGRAPH CANADA DEP, V3
[7]   A summary of taxonomic changes recently approved by ICTV [J].
Mayo, MA .
ARCHIVES OF VIROLOGY, 2002, 147 (08) :1655-1656
[8]  
*OIE, 2005, CHAPT 2 7 13 NEWC DI, P301
[9]  
1991, EUROPEAN PHARMACOPOE